Medistem Inc. (PINKSHEETS: MEDS) announced today a peer-reviewed publication led by NIH scientists demonstrating that the company’s Endometrial Regenerative Cells (ERC) possess a unique genetic signature associated with production of new blood vessels (angiogenesis).
“The demonstration by an independent group that ERC possess a unique gene signature compared to other stem cells, and that the gene signature is associated with production of new blood vessels, is a strong validation for our programs,” said Dr. Thomas Ichim, President and CSO of Medistem. “These data support original publications by our group and others that have demonstrated ERC appear to be nature's regenerative powerhouse for production of new blood vessels.”
According to the publication, the gene encoding aldehyde dehydrogenase, a marker of stem cell potency, was expressed 39.5-fold higher in ERC as compared to bone marrow mesenchymal stem cells (MSC). Additionally, genes associated with production of new blood vessels such as MMP-3, angiopoietin, and PDGF, were expressed 29-fold, 13-fold, and 26-fold higher in ERC as compared to bone marrow MSC, respectively.
“Currently the majority of scientific effort in development of stem cell therapeutics is associated with bone marrow stem cells. While bone marrow stem cells have many excellent properties, the stem cells we are clinically developing are derived from the endometrium. This is the only part of the body that renews itself every month by producing new blood vessels. The findings today that the ERC stem cell appears to have a gene signature that is different than bone marrow, further supports our hypothesis that the ERC is a unique cell that acts as the natural angiogenic 'repair cell' of the body,” said Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah.
Currently Dr. Patel is the International Investigator for the RECOVER-ERC Phase II clinical trial which involves administration of ERC into patients with heart failure via a novel 30 minute delivery process. Heart failure and critical limb ischemia, which are Medistem’s 2 clinical programs, have both been demonstrated to benefit from stimulation of new blood vessel production. Medistem has received clearance from the FDA to perform clinical trials in critical limb ischemia.
The publication may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-207.pdf
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and congestive heart failure. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.Business Wire
Last updated on: 10/10/2012